No headlines found.
Enhabit Home Health & Hospice Earns 2025 Great Place To Work Certification
Business Wire (Thu, 30-Jan 5:05 PM ET)
Business Wire (Wed, 4-Dec 8:30 AM ET)
Enhabit Announces Participation in Upcoming BofA Home Care Conference
Business Wire (Tue, 19-Nov 4:17 PM ET)
Enhabit Home Health & Hospice Appoints Ryan Solomon as Chief Financial Officer
Business Wire (Thu, 7-Nov 7:30 AM ET)
Enhabit Reports Third Quarter 2024 Financial Results
Business Wire (Wed, 6-Nov 4:19 PM ET)
Enhabit Inc provides home health and hospice services in the United States. It offers care where patients prefer it: in their homes. It operates business in two segments: home health and hospice. Its home health segment include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates the majority of its revenue from the Home Health segment.
Enhabit trades on the NYSE stock market under the symbol EHAB.
As of January 31, 2025, EHAB stock price climbed to $8.72 with 23,586 million shares trading.
EHAB has a beta of 0.49, meaning it tends to be less sensitive to market movements. EHAB has a correlation of 0.02 to the broad based SPY ETF.
EHAB has a market cap of $438.47 million. This is considered a Small Cap stock.
Last quarter Enhabit reported $254 million in Revenue and $.03 earnings per share. This fell short of revenue expectation by $-8 million and missed earnings estimates by -$.01.
The top ETF exchange traded funds that EHAB belongs to (by Net Assets): VTI, IWM, VXF, IWN, DFAT.
EHAB has underperformed the market in the last year with a return of -15.4%, while SPY returned +25.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in EHAB shares. However, EHAB has outperformed the market in the last 3 month and 2 week periods, returning +24.9% and +9.4%, while SPY returned +5.3% and +2.9%, respectively. This indicates EHAB has been having a stronger performance recently.
EHAB support price is $8.47 and resistance is $8.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EHAB shares will trade within this expected range on the day.